Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Exact Sciences Corporation or argenx SE because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Exact Sciences Corporation and argenx SE compare based on key financial metrics to determine which better meets your investment needs.
About Exact Sciences Corporation and argenx SE
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Latest Biotechnology and Exact Sciences Corporation, argenx SE Stock News
As of May 5, 2025, Exact Sciences Corporation had a $10.1 billion market capitalization, compared to the Biotechnology median of $111.9 million. Exact Sciences Corporation’s stock is down 4.9% in 2025, up 19.3% in the previous five trading days and down 11.13% in the past year.
Currently, Exact Sciences Corporation does not have a price-earnings ratio. Exact Sciences Corporation’s trailing 12-month revenue is $2.8 billion with a -36.1% net profit margin. Year-over-year quarterly sales growth most recently was 10.9%. Analysts expect adjusted earnings to reach $0.225 per share for the current fiscal year. Exact Sciences Corporation does not currently pay a dividend.
As of May 5, 2025, argenx SE had a $40.1 billion market cap, putting it in the 93rd percentile of all stocks. argenx SE’s stock is up 3.6% in 2025, up 1.2% in the previous five trading days and up 71.3% in the past year.
Currently, argenx SE’s price-earnings ratio is 51.4. argenx SE’s trailing 12-month revenue is $2.2 billion with a 37.1% net profit margin. Year-over-year quarterly sales growth most recently was 81.3%. Analysts expect adjusted earnings to reach $13.843 per share for the current fiscal year. argenx SE does not currently pay a dividend.
How We Compare Exact Sciences Corporation and argenx SE Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Exact Sciences Corporation and argenx SE’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions